1. Home
  2. BHE vs PHVS Comparison

BHE vs PHVS Comparison

Compare BHE & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Benchmark Electronics Inc.

BHE

Benchmark Electronics Inc.

HOLD

Current Price

$84.62

Market Cap

3.1B

Sector

Technology

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$30.01

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHE
PHVS
Founded
1979
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
1.8B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
BHE
PHVS
Price
$84.62
$30.01
Analyst Decision
Strong Buy
Buy
Analyst Count
3
11
Target Price
$55.00
$41.82
AVG Volume (30 Days)
416.9K
355.8K
Earning Date
04-29-2026
05-12-2026
Dividend Yield
0.94%
N/A
EPS Growth
N/A
N/A
EPS
0.36
N/A
Revenue
$2,659,108,000.00
N/A
Revenue This Year
$7.03
N/A
Revenue Next Year
$6.57
N/A
P/E Ratio
$235.91
N/A
Revenue Growth
0.11
N/A
52 Week Low
$34.44
$15.93
52 Week High
$89.40
$33.33

Technical Indicators

Market Signals
Indicator
BHE
PHVS
Relative Strength Index (RSI) 58.84 51.94
Support Level $79.49 $24.73
Resistance Level $87.71 $31.14
Average True Range (ATR) 3.16 1.47
MACD -0.81 -0.13
Stochastic Oscillator 52.47 32.80

Price Performance

Historical Comparison
BHE
PHVS

About BHE Benchmark Electronics Inc.

Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia, and Europe, of which key revenue is derived from the Americas.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: